The FDA has approved alpelisib, in combination with fulvestrant for PIK3CA mutated HR+ HER2- BC, and capivasertib in combination with fulvestrant for HR+ HER2- BC with alterations in PIK3CA/AKT1/PTEN. Here, PIK3CA is linked to breast cancer.